CD30 se expresa universalmente en las células de Reed-Sternberg en el linfoma clásico de Hodgkin e i...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-CD30-CHL |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-CHL |
| Fuentes | SRC-ESMO-HODGKIN-2024 SRC-NCCN-BCELL-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-CD30-IHC |
|---|---|
| Variante | Expresión CD30 en las células Reed-Sternberg / Hodgkin (~100% positivo por IHC — característica definitoria del linfoma Hodgkin clásico) |
| Enfermedad | DIS-CHL |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | A+AVD (brentuximab vedotin + AVD) — 1L fase III/IV cHL por SRC-NCCN-BCELL-2025, SRC-ESMO-HODGKIN-2024, brentuximab vedotin + nivolumab — R/R cHL pre-/post-auto-HCT por SRC-NCCN-BCELL-2025, brentuximab vedotin consolidation post-auto-HCT — R/R cHL de alto riesgo por SRC-NCCN-BCELL-2025 |
| Monoterapia contraindicada | brentuximab vedotin + bleomycin (pulmonary toxicity contraindication per ECHELON-1) |
| Resumen de las pruebas | CD30 is universally expressed on Reed-Sternberg cells in classical Hodgkin lymphoma and is the target of brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate (auristatin payload). 1L advanced- stage cHL: A+AVD (BV + doxorubicin/vinblastine/dacarbazine) is preferred over ABVD per ECHELON-1 (Ansell NEJM 2022 — 6y OS 93.9% vs 89.4%, HR 0.59) per SRC-NCCN-BCELL-2025, SRC-ESMO-HODGKIN-2024. Pediatric AHOD1331 supported BV + AVE-PC for high-risk pediatric. R/R cHL: BV monotherapy and BV + nivolumab are standard pre-/post- HCT options. BV consolidation post-autoHCT for high-risk R/R cHL (AETHERA Younes Lancet 2015 — improves PFS) per SRC-NCCN-BCELL-2025. |
Notas
ESCAT IA / OncoKB Level 1. CD30 IHC is universally positive in cHL, so the biomarker is essentially a histologic-confirmation gate rather than a selection threshold for the drug class. Bibliographic records SRC-ECHELON-1-CONNORS-2018 and SRC-AETHERA-MOSKOWITZ-2015 are available; SRC-CHECKMATE-744 remains a source gap and claim-level linkage requires clinical sign-off. PD-1 checkpoint inhibitors (pembrolizumab KEYNOTE-204, nivolumab CheckMate-205) are alternative biology-driven options in R/R cHL.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.